Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis (CMM/FPI)
|ClinicalTrials.gov Identifier: NCT01919827|
Recruitment Status : Active, not recruiting
First Posted : August 9, 2013
Last Update Posted : January 6, 2017
Clinical Trial Phase I, open, multicentric, non randomized, study with escalating doses, to evaluate the safety and feasibility of treatment with mesenchymal stem cells in patients with diagnosis of idiopathic pulmonary fibrosis.
Primary endpoint: The aim is to evaluate the safety and feasibility of the endobronchial administration of mesenchymal autolog stem cells derived from bone marrow (BM-MSC)in patients with mild-to-moderate idiopathic pulmonary fibrosis.
Secondary endpoint:Assess the possible effect of the infusion of BM-MSC in stopping the fall of pulmonary function in patients with mild-to-moderate idiopathic pulmonary fibrosis.
|Condition or disease||Intervention/treatment||Phase|
|Idiopathic Pulmonary Fibrosis||Biological: Endobronchial infusion of adult mesenchymal stem cells Biological: Autologous mesenchymal stem cells derived from bone marrow||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
|Experimental: MSC endobronchial infusion||Biological: Endobronchial infusion of adult mesenchymal stem cells Biological: Autologous mesenchymal stem cells derived from bone marrow|
- Number of participants with adverse side effects. [ Time Frame: Up to 12 months ]
Number of participants with adverse side effects, and according to the level of severity:
- Low level: Increase in cough, fever or skin reactions
- Medium level: Infections not requiring hospital admission, mild alterations of renal or liver function
High level: Death or major side effects requiring hospitalization:
- Worsening dyspnea with >=10% reduction in forced vital capacity, reduction in arterial pressure oxygen >= 10 mmHg and radiology progression between 3 months separated visits.
- Need for hospitalization due to respiratory failure requiring mechanical ventilation, worsening in gases exchange or lung infection.
- Carcinogenesis at 12 months after the endobronchial infusion of mesenchymal stem cells.
- Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF [ Time Frame: Up to 12 months ]
Measures of efficacy:
- Fall in forced vital capacity as a continuous variable
- Progression of the disease defined by: Death, need for transplantation or deterioration in pulmonary function defined by fall in forced vital capacity (FVC) > 10% or in lung diffusion capacity (DLCO) > 15%.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01919827
|Servicio de Neumología, Clínica Universidad de Navarra|
|Pamplona, Navarra, Spain, 31008 Pamplona|
|Servicio de Neumología. Hospital Universitario de Salamanaca|